Skip to main content
OpenTrials
Completed

NCT Number: NCT01684007

A Clinical Outcome Study of Two Multifocal Intraocular Lenses (IOL) in Cataract Patients

The purpose of this study is to compare AcrySof® IQ ReSTOR® +2.5 D Multifocal IOL in both eyes (bilateral implantation) to AcrySof® IQ ReSTOR® +2.5 D Multifocal IOL in the dominant eye with AcrySof® IQ ReSTOR® +3.0 D Multifocal IOL in the fellow eye (contralateral implantation) at Month 3 following the second eye surgery.

Completed

Looking for future studies?

Notify Me

Key information

Age range

21 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

About this study

Each subject will complete a preoperative examination of both eyes, implantation of IOL at the operative visit for each eye, and up to 4 postoperative visits (each eye examined at Day 1-2, with binocular visits at Day 30 and Day 90 after the second implantation). The second implantation will occur between 1 and 45 days of the first. If the first eye is not implanted during surgery, the second eye is not eligible. lf both eyes are not implanted with the assigned IOL, the subject will be followed for safety evaluation.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Willing and able to understand and sign informed consent, and attend postoperative examinations per protocol schedule;
  • Requires cataract extraction followed by posterior intraocular lens implantation used as an on-label procedure in both eyes;
  • Willing to have second eye surgery within 45 days of first eye surgery;
  • Expected postoperative astigmatism < 1.0 D in both eyes, as measured by keratometry;
  • Free of severe diseases(s)/condition(s) listed in the Warnings and Precautions section of the package inserts;
  • Other protocol-defined inclusion criteria may apply.

Exclusion criteria

  • Refractive lens exchange (monocular DCVA of worse than 20/20, or ≥ 0.06 logMAR). This exclusion did not apply to binocular (OU) measurement;
  • Significant irregular corneal astigmatism as demonstrated by corneal topography;
  • Severe degenerative visual disorders;
  • Previous corneal surgery;
  • Amblyopia;
  • Planned multiple procedures, including LRI, LASIK, etc, during surgery or the course of the study;
  • History of corneal disease;
  • Severe diabetic retinopathy;
  • History of retinal detachment;
  • Severe conditions or acute or chronic diseases or illnesses that, per investigator's clinical judgment, would increase the operative risk or confound the results of the study;
  • Pregnant or planning pregnancy during course of study;
  • Other protocol-defined exclusion criteria may apply.

Treatment and study plan

AcrySof® IQ ReSTOR® +2.5 D Multifocal IOL Model SN6AD2 [SV25T0]

Device

Multifocal IOL with extended secondary focal point implanted for long-term use over the lifetime of the cataract patient

AcrySof® IQ ReSTOR® +3.0 D Multifocal IOL Model SN6AD1

Device

Multifocal IOL implanted for long-term use over the lifetime of the cataract patient

Primary outcomes

  1. Binocular Distance Corrected Visual Acuity (logMAR) - Intermediate (60 cm)

    Time frame: Day 90 from second eye implantation

    Visual acuity (VA) was tested binocularly (both eyes together) using the manifest refraction adjusted for optical infinity and the hand-held, 100% contrast, Early Treatment Diabetic Retinopathy Study (ETDRS) chart set at 60 centimeters (cm) on the nearpoint rod. VA was measured in logarithm minimum angle of resolution (logMAR) increments, with 0.1 logMAR corresponding to 5 letters, or 1 line, on the ETDRS chart. A lower logMAR value denotes better visual acuity.

Secondary outcomes

  1. Binocular Distance Corrected Visual Acuity (logMAR) - Near (40 cm)

    Time frame: Day 90 from second eye implantation

    VA was tested binocularly using the manifest refraction adjusted for optical infinity and the hand-held, 100% contrast, ETDRS chart set at 40 cm on the nearpoint rod. VA was measured in logMAR increments, with 0.1 logMAR corresponding to 5 letters, or 1 line, on the ETDRS chart. A lower logMAR value denotes better visual acuity.

Sponsors and collaborators

Lead sponsor

Alcon Research

Industry

Registry information

Official study title

Clinical Outcomes After Implantation of the AcrySof® IQ ReSTOR® +2.5 D Multifocal Intraocular Lens (MIOL) in the Dominant Eye and Randomization of the AcrySof® IQ ReSTOR® +2.5 D or +3.0 D MIOL in the Fellow Eye

Important dates

Study start
2012
Primary completion
2013
Study completion
2013
First posted
Sep 12, 2012
Registry last updated
Jun 22, 2015

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.